Roivant Sciences Ltd.: president & Immunovant CEO Venker Eric sold 200,000 shares

What happened

• Venker Eric, president of Roivant Sciences Ltd. and CEO of Immunovant, exercised options and sold shares on Sep 30, 2026. The Form 4 reports an exercise/conversion (code M) of 200,000 shares at $3.85 (acquired) for $770,000; an open-market sale (code S) of 200,000 shares at a weighted average price of $36.62 (disposed) for $7,324,000; and an exercise/conversion (code M) of 200,000 shares at $0.00 (disposed) for $0.

Key details

• Transaction date: Sep 30, 2026. Sale weighted average price reported as $36.62; footnote says sale prices ranged from $36.49 to $36.76.
• Option exercise: 200,000 shares acquired at $3.85, total $770,000.
• Sale: 200,000 shares disposed at weighted avg $36.62, total $7,324,000.
• Derivative disposition: 200,000 shares exercised/converted and disposed at $0.00, total $0.
• Shares owned after the transaction: not reported in this Form 4.
• Footnotes: F1 notes the weighted average sale price and that the sales were effected under a Rule 10b5-1 trading plan adopted on Mar 28, 2025 and that full per-price details are available upon request; F2 notes an award of stock options that is fully vested.
• Filing date: Oct 2, 2026. The filing does not indicate a late report.

Why it may matter

• The filing shows options were exercised and shares sold the same day (cashless exercise).
• The sale was made under a Rule 10b5-1 trading plan and the options involved were fully vested.
• A filing does not show why the insider traded or why the company acted.